Has Ozempic Impacted Your Business?
The answer, for a staggering number of businesses in the United States, is yes. And the same is true for both businesses and industries in other industrialized nations in the world. The impact of the family of GLP-1 drugs (primarily Ozempic, Wegovy, and Mounjaro) can readily be seen affecting or influencing a wide array of societal sectors, well beyond the obvious healthcare and economic spheres.
GLP-1 | By The Numbers
- The use of GLP-1 products has increased dramatically, showing a 40-fold increase in the use of these drugs between 2017 and 2021.
- In the 4th quarter of 2022, 40 million prescriptions were written for Ozempic and related GLP-1 products.
- An estimated 1 in 8 adults in the US have used a GLP-1 product. An estimated 6% currently use the drug.
- Sales for Ozempic in the United States rose from $7.4 billion in 2022 to $12.54 billion in 2023.
- 2020-2023 data found a 594% increase in the monthly number of adolescents and young adults using GLP-1 products.
We can Help Your Business Lean Into GLP-1
Rather than compete with Ozempic and GLP-1 products, we feel there is an opportunity to lean into this trend by embracing those that use GLP-1 as part of a larger weight loss strategy, one that also includes your products and services.
We've made some additions to our application that allows you embrace GLP-1 users into your business.
Our custom program now includes:
- A tracking component that helps users monitor their GLP-1 schedule.
- An additional chart that focuses on weight loss between injections.
In conclusion, we feel that, while Ozempic can complicate the landscape, there is also an opportunity to lean into it and make it part of your business. Contact us for a live demonstration of our GLP-1 tracking components and discuss ways we can help your business move forward.
#ozempic #glp-1 #wegovy #mounjaro Back to blog index